Vor, Janssen partner on combination immunotherapy for leukemia

By The Science Advisory Board staff writers

July 8, 2021 -- Vor Biopharma is collaborating with Janssen Biotech to develop engineered hematopoietic stem cell therapies combined with targeted therapies for the treatment of cancer.

Under the collaboration, Vor will investigate the combination of Vor's "invisible" engineered hematopoietic stem cell transplant platform and Janssen's bispecific antibodies into a treatment solution for acute myeloid leukemia.

"We believe this unique combination will leverage each technology's strengths, while protecting patients against off-target effects of these powerful immunotherapies," said Tirtha Chakraborty, PhD, chief scientific officer of Vor.

As part of the agreement, each company will retain all rights and ownership to their respective programs and platforms. Additional financial details were not disclosed.

Vor, Abound Bio to develop multitargeted CAR T therapies
Vor Biopharma has entered into a multiyear strategic collaboration and license agreement with Abound Bio to research both single- and multitargeted chimeric...

Copyright © 2021 scienceboard.net


Conferences
International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter